RxDoctor Payments Data

Christopher Lenivy, DO

Pulmonary Disease · Allentown, PANPI 1184074338

Payments from drug & device makers

$4,994in general payments, 2019–2025

Across 43 payments — averaging $116.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Medical Device Business Services, Inc.$645
  • Boehringer Ingelheim$269
  • Sanofi-aventis U.S. LLC$100
  • Mylan Specialty L.p.$40
  • AstraZeneca$40
  • plus $156 from 7 others

What the payments were for

  • Travel & lodging$2,66153%
  • Food & beverage$1,71834%
  • Education$60012%
  • Gifts$150%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,994 in reported general payments places this provider in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$79,606
Medicare patients
357
Services billed
697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter175$137,979
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$35,932
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr44$29,382
Stiolto RespimatTiotropium Br/Olodaterol Hcl38$28,951
Spiriva RespimatTiotropium Bromide15$12,546
Breo ElliptaFluticasone/Vilanterol22$10,197
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$5,799
Albuterol Sulfate HfaAlbuterol Sulfate147$5,181
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$5,058
Incruse ElliptaUmeclidinium Bromide11$4,974
SymbicortBudesonide/Formoterol Fumarate12$4,216
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate23$3,684
Roflumilast15$2,925
Wixela InhubFluticasone Propion/Salmeterol12$1,095
Montelukast Sodium42$730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$14$182,532252 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$40$45,20656 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$269$41,49753 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →